Current Report Filing (8-k)
January 05 2018 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest
event reported):
January 5, 2018
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
000-19271
|
01-0393723
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
One IDEXX Drive, Westbrook, Maine
|
04092
|
(Address of principal executive offices)
|
(ZIP Code)
|
207.556.0300
(Registrant's telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02.
|
Results of Operations and Financial Condition.
|
On January 5, 2018, IDEXX Laboratories,
Inc. (the “Company”) issued a press release discussing the impact on the Company of the enactment on December 22, 2017
of the Tax Cuts and Jobs Act (the “Tax Legislation”), the full text of which is furnished as Exhibit 99.1 to this Current
Report on Form 8-K. The Company estimates, based on currently available information, that the Tax Legislation will benefit the
Company by reducing its recurring effective tax rate beginning in 2018 by approximately 750-850 basis points. The Company also
estimates that the enactment of the Tax Legislation will result in a one-time reduction of approximately $35 million - $45 million
in the Company’s earnings for the fourth quarter and year ended December 31, 2017, due to the deemed repatriation of the
Company’s foreign profits, net of the remeasurement of U.S. deferred taxes at the lower enacted corporate tax rate and other
adjustments.
The impact of the
Tax Legislation may differ from the estimates above, possibly materially, due to, among other things, changes in interpretations
and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Legislation.
The Company will continue to analyze the Tax Legislation to determine the full effects of the new law, including the new lower
corporate tax rate, on its financial statements and operations.
The Company will
announce financial results for the fourth quarter and year ended December 31, 2017 on February 1, 2018.
In accordance with general instructions
to Form 8-K, the information in this Form 8-K and Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01.
|
Regulation FD Disclosure.
|
The disclosure set forth above under Item
2.02 is incorporated by reference into this Item 7.01.
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit
shall be deemed to be furnished, and not filed.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IDEXX LABORATORIES, INC.
|
|
|
|
|
|
|
|
Date: January 5, 2018
|
By:
|
/s/ Brian P. McKeon
|
|
|
|
Brian P. McKeon
|
|
|
|
Executive Vice President, Chief Financial
Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Sep 2023 to Sep 2024